Mobius Therapeutics(TM) Announces Assignment of HCPCS Code for Mitosol(R)
CMS Assigns Code for Billing Medicare, Private Insurance
(firmenpresse) - ST. LOUIS, MO -- (Marketwire) -- 11/08/12 -- Mobius Therapeutics, LLC announced today the Centers for Medicare and Medicaid Services (CMS) has assigned a product-specific Healthcare Common Procedures Coding System (HCPCS) code for Mitosol® (mitomycin for solution) 0.2mg/vial, Kit for Ophthalmic Use. Mitosol is used as an adjunct to ab externo glaucoma surgery. The new J-code, J7315, becomes effective on January 1, 2013.
"This is an important milestone for Mobius Therapeutics, and we are very pleased that CMS has issued a J-code for Mitosol®," said Ed Timm, Chief Executive Officer and Founder of Mobius Therapeutics, LLC. "While it may take up to three months for the J-code to be loaded into the entire payer system, the J-code facilitates more rapid reimbursement for providers. Mitosol is manufactured under cGMP controls and provides assured dosing concentration with consistent potency and sterility. In light of the on-going concerns related to the sterility and quality assurance of sterile filled medications, Mitosol's quality manufacturing and convenience helps providers and patients with peace of mind."
J-codes are part of the Healthcare Common Procedure Coding System (HCPCS), and used by providers to identify medical products to facilitate reimbursement.
Mobius Therapeutics is a commercial stage venture focused on ophthalmic surgery solutions. Its first product, Mitosol®, is a system for delivering antifibrotic agents in glaucoma, refractive, and corneal surgery. The glaucoma indication is in active commercialization; the pterygium and refractive indications are awaiting approval by the Food and Drug Administration. Mobius is housed within the Center for Emerging Technologies in St. Louis, Missouri.
:
Jim Anderson
Mobius Therapeutics, LLC
314-615-6930
Andy Likes
The Vandiver Group, Inc.
314-991-4641
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 08.11.2012 - 13:30 Uhr
Sprache: Deutsch
News-ID 201141
Anzahl Zeichen: 0
contact information:
Town:
ST. LOUIS, MO
Kategorie:
Biotech
Diese Pressemitteilung wurde bisher 211 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Mobius Therapeutics(TM) Announces Assignment of HCPCS Code for Mitosol(R)"
steht unter der journalistisch-redaktionellen Verantwortung von
Mobius Therapeutics (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
